[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621038":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":33,"locations":39,"responsibleParty":211,"collaborators":23,"id":213,"slug":214,"hasResults":215,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":215,"sex":221,"minAge":222,"maxAge":23,"enrollmentInfo":223,"targetDuration":23,"studyType":226,"phases":227,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":42,"whyStopped":23,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},{"fullName":5,"class":6},"Swiss Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stage 1","EXPERIMENTAL","Patients will be randomized in a 1:1:1 ratio for a total of 9 patients per dose level to either the standard dose (250mg) or an escalated dose (500mg or 1000mg).Treatment duration: up to 12 cycles of 28 days",[13],"Drug: Terbinafine",{"label":15,"type":10,"description":16,"interventionNames":17},"Stage 2","Additional patients will be enrolled in stage II, at a selected dose level, based on the results obtained in Stage I.\n\nTreatment duration: up to 12 cycles of 28 days",[13],[19],{"type":20,"name":21,"description":13,"armGroupLabels":22,"otherNames":23},"DRUG","Terbinafine",[9,15],null,[25,29],{"name":26,"affiliation":27,"role":28},"Stefanie Fischer, PD MD","HOCH Health Ostschweiz","STUDY_CHAIR",{"name":30,"affiliation":31,"role":32},"Richard Cathomas, Prof","Cantonal Hospital Graubünden","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":23,"email":38},"Christina Müller, PhD","CONTACT","+41 31 389 91 91","trials@swisscancerinstitute.ch",[40,60,75,90,105,121,136,151,166,181,196],{"facility":41,"status":42,"city":43,"state":23,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Kantonsspital Baden","RECRUITING","Baden","5404","Switzerland","CH",{"type":48,"coordinates":49},"Point",[50,51],8.30592,47.47333,{"lat":51,"lon":50},[54,58],{"name":55,"role":36,"phone":56,"phoneExt":23,"email":57},"Andreas Erdmann, MD","+41 56 486 27 62","andreas.erdmann@ksb.ch",{"name":55,"role":59,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"facility":61,"status":42,"city":62,"state":23,"zip":63,"country":45,"countryCode":46,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Universitätsspital Basel","Basel","4031",{"type":48,"coordinates":65},[66,67],7.57327,47.55839,{"lat":67,"lon":66},[70,74],{"name":71,"role":36,"phone":72,"phoneExt":23,"email":73},"Cyrill A. Rentsch, Prof","+41 61 265 72 80","cyrill.rentsch@usb.ch",{"name":71,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":76,"status":42,"city":77,"state":23,"zip":78,"country":45,"countryCode":46,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"EOC - Istituto Oncologico della Svizzera Italiana","Bellinzona","6500",{"type":48,"coordinates":80},[81,82],9.01703,46.19278,{"lat":82,"lon":81},[85,89],{"name":86,"role":36,"phone":87,"phoneExt":23,"email":88},"Thomas Zilli, Prof","+41 91 811 85 13","thomas.zilli@eoc.ch",{"name":86,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":91,"status":42,"city":92,"state":23,"zip":93,"country":45,"countryCode":46,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Kantonsspital Graubünden","Chur","7000",{"type":48,"coordinates":95},[96,97],9.53287,46.84986,{"lat":97,"lon":96},[100,104],{"name":101,"role":36,"phone":102,"phoneExt":23,"email":103},"Angela Fischer, MD","+41 81 256 66 46","angela.fischer@ksgr.ch",{"name":101,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":106,"status":42,"city":107,"state":23,"zip":108,"country":45,"countryCode":46,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Spital Thurgau AG","Frauenfeld","8501",{"type":48,"coordinates":110},[111,112],8.89893,47.55776,{"lat":112,"lon":111},[115,119],{"name":116,"role":36,"phone":117,"phoneExt":23,"email":118},"Regina Woelky, MD","+41 58 144 76 91","regina.woelky@stgag.ch",{"name":120,"role":59,"phone":23,"phoneExt":23,"email":23},"Jeanne Godau, MD",{"facility":122,"status":42,"city":123,"state":23,"zip":124,"country":45,"countryCode":46,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Hôpitaux Universitaires Genève HUG","Geneva","1211",{"type":48,"coordinates":126},[127,128],6.14569,46.20222,{"lat":128,"lon":127},[131,135],{"name":132,"role":36,"phone":133,"phoneExt":23,"email":134},"Petros Tsantoulis, MD","+41 22 372 98 62","petros.tsantoulis@hcuge.ch",{"name":132,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":137,"status":42,"city":138,"state":23,"zip":139,"country":45,"countryCode":46,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Luzerner Kantonsspital","Lucerne","6004",{"type":48,"coordinates":141},[142,143],8.30635,47.05048,{"lat":143,"lon":142},[146,150],{"name":147,"role":36,"phone":148,"phoneExt":23,"email":149},"Christian Rothermundt, MD","+41 41 205 58 60","christian.rothermundt@luks.ch",{"name":147,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":152,"status":42,"city":153,"state":23,"zip":154,"country":45,"countryCode":46,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"TBZO Tumor- und BrustZentrum Ostschweiz - Rapperswil","Rapperswil","8640",{"type":48,"coordinates":156},[157,158],8.82228,47.22557,{"lat":158,"lon":157},[161,165],{"name":162,"role":36,"phone":163,"phoneExt":23,"email":164},"Deborah Zihler, MD","+41 55 536 13 00","deborah.zihler@tbz-ost.ch",{"name":162,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":167,"status":42,"city":168,"state":23,"zip":169,"country":45,"countryCode":46,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"HOCH Health Ostschweiz - Kantonsspital St. Gallen","Sankt Gallen","9007",{"type":48,"coordinates":171},[172,173],9.37477,47.42391,{"lat":173,"lon":172},[176,180],{"name":177,"role":36,"phone":178,"phoneExt":23,"email":179},"Stefanie Fischer, MD","+41 71 494 11 11","stefanie.fischer@h-och.ch",{"name":177,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":182,"status":42,"city":183,"state":23,"zip":184,"country":45,"countryCode":46,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Kantonsspital Winterthur","Winterthur","8401",{"type":48,"coordinates":186},[187,188],8.72413,47.50564,{"lat":188,"lon":187},[191,195],{"name":192,"role":36,"phone":193,"phoneExt":23,"email":194},"Beat Förster, MD","+41 52 266 2991","beat.foerster@ksw.ch",{"name":192,"role":59,"phone":23,"phoneExt":23,"email":23},{"facility":197,"status":42,"city":198,"state":23,"zip":199,"country":45,"countryCode":46,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Universitätsspital Zürich USZ","Zurich","8091",{"type":48,"coordinates":201},[202,203],8.55,47.36667,{"lat":203,"lon":202},[206,210],{"name":207,"role":36,"phone":208,"phoneExt":23,"email":209},"Anja Lorch, Prof","+41 43 253 02 50","anja.lorch@usz.ch",{"name":207,"role":59,"phone":23,"phoneExt":23,"email":23},{"type":212,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100621038","phase-2-terbinafine-for-biochemically-recurrent-prostate-cancer-terbinapro-100621038",false,"NCT07365423","Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)","Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) - A Phase II Drug-repurposing Study","TerbinaPro","Key Inclusion Criteria:\n\n* Patients after definitive treatment for localized prostate cancer and exhaustion of standard curative options (i.e. after prostatectomy and adjuvant \u002Fsalvage radiotherapy; definite radiotherapy, brachytherapy; additional previous Stereotactic Body Radiation Therapy (SBRT) to treat visible oligometastatic disease also allowed as long as confirmed Prostate-specific antigen (PSA) progression is present after SBRT)\n* Non-castrate levels of testosterone (≥ 5 nmol\u002Fl; previous androgen deprivation therapy (ADT) allowed as long as testosterone levels have recovered before study entry)\n* No evidence of distant metastatic disease on conventional imaging (Computed Tomography (CT) and bone scan) or Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) CT.\n* Patients with PSMA positive lymph nodes on PSMA PET CT can still be included if the short axis of the largest lymph node is \\\u003C 20 mm for lymph nodes below aortic bifurcation or \\\u003C 10 mm above the aortic bifurcation.\n* PSA of ≥1 ng\u002Fml after radical prostatectomy or ≥2 ng\u002Fml above the nadir (with recovered testosterone) after primary radiotherapy; confirmation of rising PSA in at least a second measurement at least 2 weeks apart\n* Patient declining start of ADT and \u002For an androgen receptor pathway inhibitor (ARPI) and\u002For judged as not in need of immediate ADT\u002FARPI start by treating physician\n\nKey Exclusion Criteria:\n\n* Pre-existing known chronic or acute liver disease\n* Known history of systemic lupus erythematosus or any form of lupus (including cutaneous, drug-induced, or lupus nephritis)\n* Pure neuroendocrine\u002Fsmall-cell histologic variant of prostate cancer","MALE","18 Years",{"count":224,"type":225},42,"ESTIMATED","INTERVENTIONAL",[228],"PHASE2","TerbinaPro is a phase II drug-repurposing study evaluating oral Terbinafine in patients with biochemical recurrence of prostate cancer after prior local treatment with curative intent. When local salvage strategies have been exhausted, recurrence usually reflects micro-metastatic disease without clearly visible metastases on imaging. Standard therapy with androgen deprivation or androgen-receptor pathway inhibitors can effectively control disease but is associated with substantial side effects and negative impact on quality of life. Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression. Preclinical and limited clinical data suggest potential anti-cancer activity.",[231],"Recurrent Prostate Cancer",[233,21,234,235],"recurrent prostate cancer","phase II","drug-repurposing Study","2026-03-27",{"date":238,"type":239},"2026-04-02","ACTUAL",{"date":241,"type":225},"2026-05",{"date":243,"type":225},"2030-10",{"name":5,"class":6},11]